01:55 AM EST, 11/09/2026 (MT Newswires) -- Valneva (VLA.PA) reported positive findings from two phase 2 trials of its Shigella4V2 vaccine candidate against shigellosis, an intestinal infection caused by shigella bacteria, with both studies showing a favorable safety profile and the adult trial meeting its primary endpoint. The infant trial, conducted in Kenya with 110 participants, found statistically significant increases in antibody levels against all four targeted Shigella serotypes compared with a control meningococcal vaccine, according to a Monday release. A separate US trial involving 120 adults showed a statistically significant reduction in the incidence of Shigella sonnei-associated shigellosis among vaccinated participants compared with those receiving a placebo following controlled exposure. The French specialty vaccine company said it is reviewing the full datasets to determine the next steps in clinical development.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.